FDA approves Phoxillum Renal Replacement Therapy in Acute Kidney Injury patients- Baxter
Baxter International Inc.announced the FDA has approved Phoxillum Renal Replacement Solutions (BK4/2.5 and B22K4/0) as replacement solutions in Continuous Renal Replacement Therapy (CRRT) to correct electrolyte and acid-base imbalances, and in case of drug poisoning when CRRT is used to remove dialyzable substances.
Continuous Renal Replacement Therapy (CCRT) is a dialysis modality used to treat disorders that develop as a result of Acute Kidney Injury (AKI), especially toxin accumulation, fluid overload, and both acid-base and electrolyte disturbances.
Hypophosphatemia (abnormally low concentration of phosphate in the blood) is a common electrolyte disturbance in patients treated with CRRT.
Baxter anticipates Phoxillum phosphate-containing solutions will be available in the United States in the second quarter of 2015.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins